泛核酸创新药物研究中心（ICNAM）致力于推动核酸药物（如DNA、mRNA、siRNA等）的基础理论研究、底层技术开发和临床转化应用。中心重点布局核酸技术适配新靶标发现、人工智能大分子计算、核酸药物制备及修饰技术、安全高效靶向递送技术，搭建从构想到实施的一站式核酸药物研发平台，并建立符合不同人群用药标准的核酸药物特异性、有效性和安全性评价体系。中心通过与国内外一流科研机构、制药企业和医疗机构开展深度合作，推动核酸技术在传染病、癌症、遗传病等多疾病领域的全球化应用和发展，为人类健康做出贡献。中心计划5年内获得3-5个国内外First-in-Class核酸药物临床试验研究批件、至少开展2项新药临床研究试验。

Innovation Center for Nucleic Acid Medicine (ICNAM)

The Innovation Center for Nucleic Acid Medicine (ICNAM) is dedicated to advancing the fundamental research, technology development, and clincial translation of nucleic acid drugs (such as DNA, mRNA, siRNA, etc.). The center focuses on key areas including nucleic acid technology-fittable drug target discovery, artificial intelligence-based macromolecular design, nucleic acid preparation and chemical modification technology, as well as delivey system development. We aim to establish an one-stop nucleic acid drug R&D platform, from conceptualization to implementation, and to build a high-throughput precision evaluation platform for nucleic acid drug evaluation. Through tight collaboration with top-tier research institutions, pharmaceutical companies, and medical organizations both domestically and internationally, the center strives to promote the global application and development of nucleic acid technology in various disease areas such as infectious diseases, cancer, and genetic disorders, with the ultimate goal to contribute to human health. Within the following five years, ICNAM plans to obtain domestic or international clinical trial approvals for 3-5 First-in-Class nucleic acid drugs and initiate at least 2 clincial trials.